Inhibition of bone morphogenic protein 4 restores endothelial function in db/db diabetic mice

Arterioscler Thromb Vasc Biol. 2014 Jan;34(1):152-9. doi: 10.1161/ATVBAHA.113.302696. Epub 2013 Nov 7.

Abstract

Objective: Bone morphogenic protein 4 (BMP4) is involved in the development of endothelial dysfunction in hypertension. This study investigated whether the inhibition of BMP4 signaling improves endothelial function in db/db diabetic mice.

Approach and results: Male db/db mice were treated with noggin via osmotic pump infusion (1 µg/[h·kg(-1)]) for 2 weeks. Adenovirus BMP4-short hairpin RNA was introduced via tail vein injection at a dosage of 10(9) pfu/mouse and its effects were examined 7 days after. Vasoreactivity was studied on wire and pressure myograph. Both noggin treatment and adenovirus BMP4-short hairpin RNA transduction improved endothelium-dependent relaxations in aortae and flow-mediated dilatation in mesenteric arteries of db/db mice. Ex vivo treatment with BMP4 inhibitors and adenovirus BMP4-short hairpin RNA rescued the impaired endothelium-dependent relaxations in db/db mouse aortae and reduced reactive oxygen species overproduction determined by dihydroethidium staining, CM-H2DCFDA fluorescence imaging, and chemiluminescence assay in db/db mouse aortae, and also in ex vivo cultured C57BL/6 mouse aortae or primary mouse aortic endothelial cells treated with high glucose. Likewise, activin receptor-like kinase 3 silencing by short hairpin RNA lentivirus improved endothelium-dependent relaxations in db/db mouse aortae accompanied by reactive oxygen species inhibition in endothelial cells. In addition, noggin reduced BMP4 upregulation in high-glucose-treated endothelial cells and in C57BL/6 mouse aortae and in aortae from db/db mice.

Conclusions: Inhibition of BMP4/activin receptor-like kinase 3/reactive oxygen species signaling improved endothelial function in diabetic mice through limiting oxidative stress in endothelium. Inhibiting BMP4 cascade can become another potential therapeutic strategy against diabetic vascular dysfunction.

Keywords: bone morphogenetic protein 4, mouse; diabetes mellitus; endothelial dysfunction; reactive oxygen species.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylcholine / pharmacology
  • Adenoviridae / genetics
  • Animals
  • Blood Glucose / metabolism
  • Bone Morphogenetic Protein 4 / antagonists & inhibitors*
  • Bone Morphogenetic Protein 4 / genetics
  • Bone Morphogenetic Protein 4 / metabolism
  • Bone Morphogenetic Protein Receptors, Type I / metabolism
  • Carrier Proteins / pharmacology*
  • Cells, Cultured
  • Diabetic Angiopathies / genetics
  • Diabetic Angiopathies / metabolism
  • Diabetic Angiopathies / physiopathology
  • Diabetic Angiopathies / therapy*
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Endothelium, Vascular / drug effects*
  • Endothelium, Vascular / metabolism
  • Endothelium, Vascular / physiopathology
  • Genetic Therapy / methods*
  • Genetic Vectors
  • Human Umbilical Vein Endothelial Cells / drug effects
  • Human Umbilical Vein Endothelial Cells / metabolism
  • Humans
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Nitric Oxide / metabolism
  • Oxidative Stress / drug effects
  • RNA Interference*
  • Reactive Oxygen Species / metabolism
  • Signal Transduction / drug effects
  • Time Factors
  • Transfection
  • Vasodilation / drug effects*
  • Vasodilator Agents / pharmacology

Substances

  • Blood Glucose
  • Bmp4 protein, mouse
  • Bone Morphogenetic Protein 4
  • Carrier Proteins
  • Reactive Oxygen Species
  • Vasodilator Agents
  • noggin protein
  • Nitric Oxide
  • Bmpr1a protein, mouse
  • Bone Morphogenetic Protein Receptors, Type I
  • Acetylcholine